SequelSEC

CV Sciences, Inc. CVSI

Pharmaceutical Preparations · CIK 0001510964 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$12.74M
Fiscal year ended 2026-06-30
Operating income
-$969.00K
Fiscal year ended 2026-06-30
Free cash flow
-$522.00K
Fiscal year ended 2026-06-30

CV Sciences, Inc. (CVSI) reported revenue of $12.74M and net income of -$2.01M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CV Sciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CV Sciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$12.74M
Cost of revenue$6.48M
Gross profit$6.26M
Operating income-$969.00K
Net income-$2.01M
Research & development$78.00K
Weighted-average diluted sharesUnavailable
Pretax income-$2.00M
Income tax expense$7.00K
Diluted EPSUnavailable
Selling, general & administrative$7.15M
General & administrative$2.85M
Selling & marketingUnavailable

Balance

CV Sciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$6.52M
Current assets$4.88M
Total liabilities$4.95M
Current liabilities$4.94M
Total equity incl. NCI$1.57M
Temporary (mezzanine) equityUnavailable
Inventory$3.96M
Accounts receivable$348.00K
Goodwill$999.00K
Long-term debt$0
Accounts payable$1.06M

Cash flow

CV Sciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$492.00K
Capital expenditures$30.00K
Investing cash flow-$30.00K
Financing cash flow-$98.00K
Net change in cash-$620.00K
Stock-based compensation$543.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$97.00K

Derived

CV Sciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$522.00K
Gross margin49.1%
Operating margin-7.6%
FCF margin-4.1%
SBC / revenue4.3%
Current ratio0.99x
Revenue YoY growth-14.9%
Net margin-15.7%
R&D / revenue0.6%
CapEx / revenue0.2%
Long-term debt / equity0.00x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CVSI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.